Study #2021-1174
Phase II trial of the PARP inhibitor Niraparib and PD-1 inhibitor Dostarlimab in patients with advanced cancers with active progressing brain metastases (STARLET)
MD Anderson Study Status
Enrolling
Treatment Agent
Niraparib, Dostarlimab
Description
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Brain Metastases
Study phase:
Phase II
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-635-1016
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.